From Yahoo Finance: 2025-05-13 08:48:00

Nurix Therapeutics, Inc. (NRIX) is featured as one of the top low-priced biotech stocks to buy now. Analyst Michael Yee highlights how tariffs and policy risks are impacting the biotech sector, causing uncertainty but potentially creating buying opportunities once resolved. The sector faces challenges like sector-specific tariffs and most favored nations policy, which could drop drug prices by 40-50%.

Despite these challenges, many biotech stocks are trading at decade-low P/E multiples, presenting potential opportunities for investors. The most favored nations policy, where the US pays 40-50% more for drugs compared to other developed nations, is not new. The US government negotiates 15-20 drugs per year, aiming to lower drug prices in the country.

Nurix Therapeutics, Inc. (NRIX) is a clinical-stage biopharmaceutical company focused on developing innovative treatments for inflammatory conditions, cancer, and other diseases. Analysts like Gil Blum and Biren Amin maintain a Buy rating on NRIX due to its promising preclinical data and innovative capabilities. The company’s advancements position it well to develop groundbreaking therapies, making it a potential investment opportunity.

Nurix Therapeutics, Inc. (NRIX) ranks 7th on the list of top low-priced biotech stocks to invest in. While NRIX shows promise, other AI stocks may offer higher returns in a shorter time frame. Investors interested in AI stocks with significant growth potential should explore options beyond NRIX, such as the cheapest AI stock trading at less than 5 times its earnings.



Read more at Yahoo Finance: Why Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy Now